Table 2 Volume of treatment courses described in the literature for hospitalised patients
From: Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009
Treatment name | Number of publications reporting use | Total number of patients receiving treatment1 | Median (IQR) number of patients receiving treatment per publication2 | FDA drug approval status for use in influenza in 2009 |
|---|---|---|---|---|
Oseltamivir | 154 | 31,737 | 63 (21–188) | Approved for acute uncomplicated influenza, expanded under EUA April 2009 |
Zanamivir | 54 | 368 | 2 (1–9) | Approved for acute uncomplicated influenza, expanded under EUA April 2009 |
Peramivir | 14 | 403 | 1 (1–3) | Unapproved, eIND in April 2009, EUA October 2009 |
Amantadine | 11 | 86 | 3 (1–13) | Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated |
Rimantadine | 5 | 32 | 3 (1–13) | Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated |
Ribavirin | 5 | 34 | 2 (1–6) | Not approved for influenza |
Intravenous immunoglobulin | 4 | 44 | 4 (2–20) | Not approved for influenza |
Chinese medicines | 3 | 1051 | 245 (56–750) | Not approved for influenza |
Convalescent Plasma | 2 | 52 | 26 | Not approved for influenza |
Macrolides3 | 1 | 31 | 31 | Not approved for influenza |
Sirolimus | 1 | 19 | 19 | Not approved for influenza |
Statins3 | 1 | 12 | 12 | Not approved for influenza |